Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interstitial lung disease in systemic sclerosis].

Luc Mouthon1, Alice Berezné, Michel Brauner

  • 1Service de Médecine Interne, Hôpital Cochin, Centre de Référence pour les Vascularites et la Sclérodermie Systémique, AP-HP, Paris. luc.mouthon@cch.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Pulmonary sarcoïdosis presenting as acute hypoxemic respiratory failure.

Respiratory medicine and research·2026
Same author

Evaluation of serial cardiovascular magnetic resonance monitoring and immunosuppressive therapy in predicting outcomes in systemic sclerosis.

RMD open·2026
Same author

Considering molecular pharmacology for sarcoidosis treatment.

The Lancet. Respiratory medicine·2026
Same author

Polyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case-control study.

Rheumatology (Oxford, England)·2025
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) affects up to 75% of diffuse SSc patients. While generally stable with a better prognosis than idiopathic ILD, SSc-ILD remains a leading cause of mortality.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Internal Medicine

Background:

  • Interstitial lung diseases (ILD) are a significant complication of systemic sclerosis (SSc), particularly in patients with diffuse disease.
  • While ILD can occur in limited cutaneous SSc, it is more prevalent in diffuse SSc, affecting up to 75% of these patients.
  • Regular screening for ILD using high-resolution computed tomography and pulmonary function tests (TLCO) is crucial for SSc patients.

Purpose of the Study:

  • To summarize the current understanding of SSc-associated ILD, including its prevalence, characteristics, prognosis, and treatment.
  • To highlight the differences between SSc-ILD and idiopathic ILD.
  • To discuss the limited efficacy of current treatments and potential therapeutic avenues.

Main Methods:

Related Experiment Videos

  • Review of existing literature on SSc-associated ILD.
  • Analysis of screening methods and diagnostic criteria.
  • Evaluation of treatment strategies and their outcomes.

    • Main Results:

    • SSc-associated ILD is common, especially in diffuse SSc, but often remains stable and has a better prognosis than idiopathic ILD due to its nonspecific nature.
    • Despite a generally favorable course, ILD is a leading cause of mortality in SSc patients.
    • Current treatments, including antifibrotics and cyclophosphamide, have shown limited benefit for SSc-ILD.

    Conclusions:

    • SSc-associated ILD requires regular monitoring, but its generally stable nature and better prognosis distinguish it from idiopathic ILD.
    • Despite its better prognosis, ILD is a major cause of death in SSc patients, underscoring the need for effective therapies.
    • Treatment options for SSc-ILD are limited, with cyclophosphamide showing minimal efficacy; however, a subset of rapidly progressive cases may benefit from specific regimens.